CADL — Candel Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1841387 ·
Last close
$5.40
Market Cap
$423.61M
52W High
$14.00
52W Low
$4.35
ADV30
1,370,954
Next earnings
2026-11-13
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -22,958,000 -21,873,000 211,110,000 203,116,000 79,519,000
Jun 2026 0 — -26,724,000 -38,905,000 208,149,000 201,565,000 82,019,000
Mar 2026 0 — -16,262,000 -8,861,000 201,920,000 194,834,000 63,891,000
Dec 2025 0 — -15,663,000 -29,496,000 125,195,000 119,731,000 73,273,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-56,023,000
Investing CF
$-1,270,000
Financing CF
$158,321,000
CapEx
$-1,297,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-278,153,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-83,815,000
Pretax Income TTM
$-88,531,000
Interest Exp TTM
$4,716,000
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -48,177,000 -38,182,000 125,195,000 73,273,000 51,922,000 -38,311,000
Dec 2024 0 -33,371,000 -55,177,000 106,866,000 40,539,000 66,327,000 -27,023,000
Dec 2023 0 -38,391,000 -37,939,000 41,201,000 28,456,000 12,745,000 -34,244,000
Dec 2022 125,000 -34,674,000 -18,794,000 77,691,000 29,977,000 47,714,000 -31,419,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-88,531,000
OpCashFlow TTM
—
Assets (Latest)
$208,149,000
Forward EPS
$-1.47

Max Pain — expiry 2027-01-15

max pain strike: $7.00 · spot: $5.32 · call oi: 5,393 · put oi: 798
Expected Move to 2027-01-15: ±$2.30 (43.23%) — implied range $3.02 – $7.62 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IRLA IRulya Therapeutics Inc. $416.85M $38.45 —
DNA Ginkgo Bioworks Holdings, Inc. $448.81M $8.32 —
TECX Tectonic Therapeutic, Inc. $392.55M $20.08 —
ALEC Alector, Inc. $381.13M $2.56 —
RGNX REGENXBIO Inc. $478.73M $7.24 —

News headlines (Yahoo Finance, 1h cache)

PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month
2026-11-16 16:42 · Yahoo
Candel Therapeutics (CADL) Stock Fair Value Moves Lower After Analysts Cut Targets
2026-11-15 09:09 · Yahoo
CADL Stock Heads For Worst Ever Session — Stifel Expects Prostate Cancer Drug Launch To Be Pushed to Mid-2028
2026-11-13 14:41 · Yahoo
Candel Therapeutics stock plummets 35% on prostate cancer BLA delay
2026-11-13 14:17 · Yahoo
CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027
2026-11-12 23:13 · Yahoo
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-12 21:05 · Yahoo
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
2026-11-06 14:00 · Yahoo
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:05 · Yahoo
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-02 21:05 · Yahoo
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
2026-10-29 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.